LONDON – The pressure on Actelion Ltd. is intensifying after a U.S. jury said the company should pay out $547 million in its license dispute with Asahi Kasei Pharma Corp of Tokyo.

LONDON – A study has produced new clues to help explain the long-standing mystery of how people with sickle cell trait are protected against severe malaria.

Jerusalem-based Teva Pharmaceutical Industries Ltd. announced Monday that it will acquire Frazer, Pa.-based Cephalon Inc. for $6.8 billion in cash, trumping Valeant Pharmaceutical International Inc.'s recent hostile bid of $5.7 billion.